Literature DB >> 10993272

Hodgkin/Reed-Sternberg cells and Hodgkin's disease in patients with B-cell chronic lymphocytic leukaemia: an immunohistological, molecular and clinical study of four cases suggesting a heterogeneous pathogenetic background.

E Pescarmona1, P Pignoloni, F R Mauro, R Cerretti, A P Anselmo, F Mandelli, C D Baroni.   

Abstract

We report the immunohistological, molecular and clinical findings in four patients affected by B-cell chronic lymphocytic leukaemia (CLL) who developed "Richter's syndrome with Hodgkin's disease (HD) features" or "CLL with Hodgkin's transformation", all characterised by the presence of typical Hodgkin/Reed-Sternberg (H/RS) cells in lymph node biopsies. In three cases the nodal involvement by CLL was demonstrated both by the presence of a predominant background of CD5/CD19/CD23+ small lymphocytes and an IgH monoclonal rearrangement revealed by PCR analysis. Conversely, in the remaining case there was neither immunohistological nor molecular evidence of lymph node involvement by CLL. In all four cases H/RS cells were Epstein-Barr virus (EBV) latent membrane protein (LMP-1) positive. These findings suggest that the presence of H/RS cells in the first three patients, who had CLL/HD nodal involvement, might be related to transformation or clonal evolution of CLL cells in H/RS cells, which is in keeping with use of the term "CLL with Hodgkin's transformation". In the fourth case a de novo HD may be postulated, representing a second malignancy presumably not clonally related to CLL. In all cases a key pathogenetic role of EBV is suggested by the expression of LMP-1 in H/RS cells. Our findings indicate that the presence of typical H/RS cells in lymph node biopsies in CLL patients may reflect a heterogeneous pathogenetic background. The different clinico-pathologic settings should be taken into consideration because of their possible implications for patients' treatment and prognosis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10993272     DOI: 10.1007/s004280000214

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  7 in total

Review 1.  Recent advances in the diagnosis and therapy of Richter's syndrome.

Authors:  Ronan Swords; John Bruzzi; Francis Giles
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

2.  Epstein-Barr virus infection and chronic lymphocytic leukemia: a possible progression factor?

Authors:  Riccardo Dolcetti; Antonino Carbone
Journal:  Infect Agent Cancer       Date:  2010-11-22       Impact factor: 2.965

3.  Hodgkin lymphoma variant of Richter transformation: morphology, Epstein-Barr virus status, clonality, and survival analysis-with comparison to Hodgkin-like lesion.

Authors:  Wenbin Xiao; Wayne W Chen; Lynn Sorbara; Theresa Davies-Hill; Stefania Pittaluga; Mark Raffeld; Elaine S Jaffe
Journal:  Hum Pathol       Date:  2016-05-14       Impact factor: 3.466

4.  MDR-1 gene polymorphisms G2677T and C3435T in a case of Hodgkin's variant of Richter's syndrome.

Authors:  Giuseppa Penna; Alessandro Allegra; Andrea Alonci; Mohamed Aguennouz; Antonino Cannavò; Sabina Russo; Angela Granata; Caterina Musolino
Journal:  Oncol Lett       Date:  2011-01-20       Impact factor: 2.967

5.  Hodgkin's disease variant of Richter's transformation: a case report.

Authors:  Abdurrahman Isikdogan; Orhan Ayyildiz; Hüseyin Büyükbayram; Ekrem Müftüoğlu
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

6.  Transformation of monoclonal B lymphocytosis to Epstein-Barr virus-positive large B-cell lymphoma with intermediate features between diffuse large B-cell lymphoma and classic Hodgkin lymphoma.

Authors:  Ying Liu; Caleb Ho; Mikhail Roshal; Jeeyeon Baik; Maria Arcila; Yanming Zhang; Ahmet Dogan; Wenbin Xiao
Journal:  AJSP Rev Rep       Date:  2019 Sep-Oct

7.  Chronic lymphocytic leukemia (CLL) with Reed-Sternberg-like cells vs Classic Hodgkin lymphoma transformation of CLL: does this distinction matter?

Authors:  Rebecca L King; Alia Gupta; Paul J Kurtin; Wei Ding; Timothy G Call; Kari G Rabe; Saad S Kenderian; Jose F Leis; Yucai Wang; Susan M Schwager; Susan L Slager; Neil E Kay; Amber Koehler; Stephen M Ansell; David J Inwards; Thomas M Habermann; Min Shi; Curtis A Hanson; Matthew T Howard; Sameer A Parikh
Journal:  Blood Cancer J       Date:  2022-01-28       Impact factor: 11.037

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.